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Abstract
Introduction: To date, no single most-appropriate factor or delivery method has been identified for the purpose
of mesenchymal stem cell (MSC)-based treatment of cartilage injury. Therefore, in this study we tested whether
gene delivery of the growth factor Indian hedgehog (IHH) was able to induce chondrogenesis in human primary
MSCs, and whether it was possible by such an approach to modulate the appearance of chondrogenic
hypertrophy in pellet cultures in vitro.
Methods: First-generation adenoviral vectors encoding the cDNA of the human IHH gene were created by cre-lox
recombination and used alone or in combination with adenoviral vectors, bone morphogenetic protein-2 (Ad.BMP-
2), or transforming growth factor beta-1 (Ad.TGF-b1) to transduce human bone-marrow derived MSCs at 5 × 102
infectious particles/cell. Thereafter, 3 × 105 cells were seeded into aggregates and cultured for 3 weeks in serum-
free medium, with untransduced or marker gene transduced cultures as controls. Transgene expressions were
determined by ELISA, and aggregates were analysed histologically, immunohistochemically, biochemically and by
RT-PCR for chondrogenesis and hypertrophy.
Results: IHH, TGF-b1 and BMP-2 genes were equipotent inducers of chondrogenesis in primary MSCs, as
evidenced by strong staining for proteoglycans, collagen type II, increased levels of glycosaminoglycan synthesis,
and expression of mRNAs associated with chondrogenesis. IHH-modified aggregates, alone or in combination, also
showed a tendency to progress towards hypertrophy, as judged by the expression of alkaline phosphatase and
stainings for collagen type X and Annexin 5.
Conclusion: As this study provides evidence for chondrogenic induction of MSC aggregates in vitro via IHH gene
delivery, this technology may be efficiently employed for generating cartilaginous repair tissues in vivo.
Introduction
None of the current approaches to cartilage regenera-
tion, including cell-based therapies, have generated
long-lasting hyaline neo-cartilage repair tissue in vivo
[1]. By means of microfracture treatment, which allows
mesenchymal stem cells (MSCs) from the subchondral
bone to enter the cartilage defect, MSC-based treat-
ments of cartilage lesions have become part of our daily
clinical routine. But administration of ex vivo amplified
MSCs to repair full-thickness articular cartilage defects
in humans has also been introduced into the clinical
arena as an alternative to transplantation of autologous
chondrocytes [2,3]. However, for such MSC-based thera-
peutic interventions to be successful, the creation of an
appropriate three-dimensional environment that allows
induction of chondrogenesis and maintenance of the
chondrogenic phenotype in vivo is of key importance
[1,4]. To achieve this goal probably requires administra-
tion of appropriate growth factors at adequate doses,
which facilitate the desired aspects of repair. Among
these growth factors, the members of the transforming
growth factor beta (TGF-b) superfamily have been most
extensively analysed, along with many others [5,6].
Furthermore, to overcome the limitations of inadequate
delivery of the soluble factors for chondrogenic induc-
tion and maintenance, genetic interventions have been
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explored clinically [7] and extensively in experimental
models in vitro and in vivo [8-10].
Remarkably, despite the fast-growing body of literature
on this topic, no single most-appropriate factor and deliv-
ery method has been identified for the purpose of hyaline
cartilage regeneration that justified approval for testing in
humans. One hurdle that might impair stable neo-cartilage
formation is the issue of chondrogenic hypertrophy, which
has been identified in studies on MSC-mediated chondro-
genesis using several bone morphogenetic proteins
(BMPs) in vitro and in vivo [1,8,11-13]. When analysing
such models, it appears that BMP-2 and others not only
drive MSCs toward chondrogenesis, but also mediate end-
stage chondrocyte maturation, hypertrophy and apoptosis,
which concurs with endochondral ossification during limb
development but is unwanted in cartilage defects [1]. In
this context, modulators of chondrogenic hypertrophy in
the growth plate such as parathyroid hormone-related
peptide (PTHrP) and Indian hedgehog (IHH) [14] appear
to be of great interest for the development of MSC-based
cartilage repair approaches. Therefore, having extensively
explored chondrogenesis in primary MSCs along with the
issue of hypertrophy following adenoviral-mediated gene
delivery of TGF-b1 and BMP-2 in previous work using
pellet cultures in vitro [8,11,15], the purpose of this study
was to explore the effects of IHH gene transfer in this
model.
Materials and methods
Generation and propagation of recombinant adenoviral
vectors
The full-length cDNA clone of the human IHH gene
[GenBank:BC034757, GenBank:BI517875] was released
from the carrier pCMV-SPORT6 plasmid (MGC-34815;
American Type Culture Collection, Manassas, VA, USA)
and the 1.4 kB insert was cloned into Xba/Xho sites of
the pAdlox adenoviral shuttle vector [16] according to
standard protocols [17]. First-generation, E1-deleted and
E3-deleted, serotype 5 adenoviral vectors carrying the
cDNAs for human IHH were constructed by cre-lox
recombination as described earlier [16] and were desig-
nated Ad.IHH. The vectors encoding GFP from jellyfish,
TGF-b1 and BMP-2 were generated, amplified, purified
and used as described earlier [11,16,18]. Virus stock titres
were determined by optical density at 260 nm and stan-
dard plaque assay, and ranged between 1012 and 1013
particles/ml.
Transduction and culture of human marrow-derived MSCs
Human bone marrow-derived MSCs were isolated from
marrow reamings of femurs from five patients, aged 48
to 62 years (mean age 54 years), undergoing total hip
replacement surgery after informed consent and as
approved by the institutional review board of the
University of Würzburg as described earlier [11,19].
Briefly, the collected cells were spun, resuspended and
placed in tissue culture using complete DMEM contain-
ing 10% foetal bovine serum and 1% penicillin/strepto-
mycin, 1 ng/ml fibroblast growth factor-2 (all Invitrogen
GmbH, Darmstadt, Germany). At confluency, cells were
trypsinised, counted, replated and transduced at 5 × 102
infectious particles/cell for each vector for 2 hours.
Marker gene controls were also maintained along with
cultures that remained uninfected and received, or not,
supplementation with recombinant 10 ng/ml TGF-b1
protein (R&D Systems, Minneapolis, MN, USA).
Pellet culture and assessment of transgene expression
Following infection, MSCs were placed in pellet cultures
as previously described [11]. Briefly, MSCs were sus-
pended in serum-free DMEM containing 1 mM pyruvate,
1% ITS+ Premix, 37.5 mg/ml ascorbate-2-phosphate and
10-7 M dexamethasone (all Sigma, St Louis, MO, USA),
and then 300 μl aliquots (3 × 105 cells) were distributed
to a polypropylene, V-bottomed 96-well plate (Corning,
Corning, NY, USA) to promote aggregate formation. As
already mentioned, control aggregates were maintained
that remained uninfected and received, or not, 10 ng/ml
TGF-b1 recombinant protein (all R&D Systems). Pellets
formed within 24 hours and cultures were maintained at
37°C, 5% CO2 with changes of fresh media being per-
formed every 2 to 3 days until harvest at various time
points for further analyses. Twenty-four-hour-condi-
tioned media were collected at several time points and
assayed for TGF-b1, BMP-2 (R&D Systems) and IHH
(Cusabio Biotech Co. Ltd, Newark, DE, USA) expression
using commercially available ELISA kits.
Osteogenic and adipogenic differentiation
For confirmation of the multilineage differentiation plasti-
city, selected MSC preparations were additionally tested
for their capacity to differentiate along osteogenic or adi-
pogenic lineages as described earlier [20]. MSC monolayer
cultures were therefore seeded at a density of 1 × 105
cells/cm2 in four-well chamber slides (Nunc, Wiesbaden,
Germany). For osteogenic induction, media were supple-
mented with 10-7 M dexamethasone, 50 μg/ml ascorbate,
10 mM b-glycerophosphate, and 25 ng/ml recombinant
human BMP-2 (R&D Systems). Adipogenesis was induced
on separate monolayer cultures by supplementing the
media with 1 μM dexamethasone, 1 μg/ml insulin,
0.5 mM 3-isobutyl-1-methylxanthine and 100 μM indo-
methacin (all Sigma). Control cultures without osteogenic
or adipogenic supplements were also maintained. After
3 weeks, cultures were fixed and osteogenic cultures were
stained histochemically for alkaline phosphatase (ALP;
Sigma) or for matrix mineralisation using Alizarin Red
(Sigma), while adipogenic cultures were stained with Oil
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Red O for the detection of lipid droplets as previously
reported [20].
Biochemical assays
Biochemical analyses for assessment of cell proliferation,
glycosaminoglycan (GAG) synthesis and ALP activity were
performed as described previously and as directed by the
respective supplier [11]. Briefly, to evaluate cell prolifera-
tion a quantitative detection of ATP was performed using
the CellTiter-Glo® Luminescent Cell Viability Assay (Pro-
mega, Madison, WI, USA). GAG contents were measured
following papain digestion (1 μg/ml; Sigma) by reaction
with 1,9-dimethylmethylene blue using the Blyscan™
Sulfated Glycosaminoglycan Assay (Biocolor Ltd, Newtow-
nabbey, Northern Ireland). ALP activity in aggregates was
analysed using a kit (Sigma) via absorbance at 405 nm by
the conversion of p-nitrophenyl phosphate to p-nitrophe-
nol and inorganic phosphate in an ELISA reader, using a
standard curve. Values of the GAG and ALP assays were
normalised to DNA content, as determined by the Quant-
iT™ PicoGreen® kit (Invitrogen).
Histology and immunohistochemistry
Histological analyses were performed on aggregates fixed
in 4% paraformaldehyde, following dehydration, paraffin
embedding, sectioning and staining with H & E and Alcian
Blue (all Sigma) as outlined previously [11]. ALP staining
was performed using a histochemical ALP staining kit
according to the manufacturer’s instructions (Sigma).
Alternate sections were subjected to immunohistochemis-
try using pre-digestions and antibody treatments as fol-
lows: collagen (COL) type II - pepsin (1 mg/ml; Sigma)/
monoclonal anti-COL type II antibodies (Acris Antibodies
GmbH, Hiddenhausen, Germany); chondroitin-4-sulphate
(CS4) - chondroitinase ABC (5 U/ml; Sigma)/polyclonal
anti-CS4 antibodies (Millipore GmbH, Schwalbach, Ger-
many); and COL type × - 0.25% trypsin (Sigma)/polyclonal
anti-COL type X antibodies (Calbiochem, Bad Soden,
Germany). Immunostainings were visualised by treatment
with Advance™ HRP link and Advance™ HRP enzyme
(Dako, Hamburg, Germany), followed by diaminobenzi-
dine staining (DAB Kit; Sigma). The slides were finally
counterstained with hemalaun (Merck, Darmstadt, Ger-
many). For all immunohistochemical analyses, controls
were performed with non-immune IgG (Sigma) instead of
the primary antibodies.
Annexin 5 assay
Annexin 5 expression was assessed as a marker of hyper-
trophy and apoptosis as described previously [11], and as
directed by the supplier (Sigma). Briefly, the test uses dou-
ble-labelling with the red fluorochome Cy3.18/Annexin 5-
Cy3 that binds to early apoptotic cells and conversion of
6-carboxyfluorescein diacetate (nonfluorescent) to 6-car-
boxyfluorescein (green fluorescent) by living cells. Follow-
ing incubation with double-labelling staining solution for
10 minutes, aggregates were washed, fixed in 4% parafor-
maldehyde, and processed to paraffin sections at 4 μm.
Evaluation of living and apoptotic cells was performed on
representative sections using a fluorescence microscope
and the appropriate green and red filters.
RNA extraction and RT-PCR analyses
On days 3, 7, 14 and 21 RNA was extracted from six to
10 MSC aggregates per group and donors using 1 ml
Trizol reagent (Invitrogen) and an additional purifica-
tion step with separation columns including a DNase
treatment according to the manufacturer’s instructions
(NucleoSpin RNA II Kit; Macherey-Nagel GmbH,
Düren, Germany). RNA from pellets of each condition
(2 μg each group) was used for reverse transcription
using random hexamer primers and BioScript reverse
transcriptase (Bioline GmbH, Luckenwalde, Germany).
Equal amounts (100 ng) of each cDNA were used as
templates for PCR amplification in a 30 μl reaction
volume using MangoTaq DNA Polymerase Taq (Bioline
GmbH) and 5 pmol of gene-specific primers as listed in
Table 1, with elongation factor-1a (EF-1a) serving as
the housekeeping gene and internal control. The RT-
PCR products were run on 1.5% agarose gels containing
0.1 mg/ml ethidium bromide, and were visualised using
the Bio Profile software (LTF, Wasserburg, Germany).
For semi-quantitative PCR analyses, equal amounts
(100 ng) of each cDNA were used as templates for
amplification in a 30 μl reaction volume using Mango-
Taq DNA Polymerase Taq (Bioline GmbH) and 5 pmol
of gene-specific primers, which were used to detect
mRNA transcripts characteristic of chondrogenic, hyper-
trophic or osteogenic differentiation states. The
sequences, annealing temperatures and product sizes of
forward and reverse primers used for COL type II,
aggrecan core protein (AGN), cartilage oligomeric
matrix protein (COMP), fibromodulin, sex determining
region Y-box 9 (SOX9), COL type I, COL type X, osteo-
pontin (OP), and osteocalcin are listed in Table 1, with
EF-1a serving as the housekeeping gene and internal
control. The RT-PCR products were electrophoretically
separated on 1.5% agarose gels containing 0.1 mg/ml
ethidium bromide and visualised using Bio Profile soft-
ware (LTF), allowing correlation between EF-1a signals
and cycle number for each sample. The densities of the
PCR bands were analysed with the Bio 1D/Capt MW
software (LTF), and the mean ratio (fold change) and
standard deviation, normalised to expression of the EF-
1a housekeeping gene, were calculated from three
bands (one per patient).
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Statistical analysis
Data from the ELISA, ATP, GAG, DNA, ALP and PCR
analyses were expressed as mean values ± standard
deviation, with each experiment being performed in tri-
plicate or quadruplicate (n = 3 to 4), and were repeated
on at least three to five individual marrow preparations
from different patients (n = 3 to 5), as indicated in the
respective experiments. Numerical data for ATP, GAG,
DNA, and ALP were subjected to variance analysis
(one-factor or two-factor analysis of variance), and sta-
tistical significance was determined by Student’s t test
with P < 0.05 considered significant.
Results
Multilineage differentiation
Pellet cultures of MSCs derived from bone marrow
underwent chondrogenic differentiation in the presence,
but not in the absence, of TGF-b1 as judged by strong
metachromatic staining of proteoglycans with Alcian
blue (Figure 1, left panels). Monolayer cultures of MSCs
responded equivalently to osteogenic or adipogenic
medium in terms of strong staining for ALP, mineralisa-
tion with Alizarin Red (Figure 1, middle panels), or
staining with Oil Red O for lipid droplets (Figure 1,
right panels), while only weak staining was observed in
the respective control cultures.
Transgene expression of genetically modified pellet
cultures
Pellet cultures modified with adenoviral vectors encoding
IHH alone or together with TGF-b1 or BMP-2 generated
high levels of transgene product at day 3 of culture, with
dose ranges of 150 to 250 pg/ml for IHH (Figure 2a), 15 to
20 ng ng/ml for TGF-b1 (Figure 2b) and 120 to 160 ng/ml
for BMP-2 (Figure 2c), and declining values over time as
evidenced by ELISA. This corresponds to previous findings
using adenoviral vectors alone [8,11,15] or in combination
[11]. The respective values in the marker gene controls
(Figure 2a to 2c) were persistently very low (< 10 pg/ml),
and were equivalent to the levels observed in the naïve
controls (data not shown).
Histological and immunohistochemical analyses of
chondrogenesis
Transduction of MSCs with Ad.IHH (IHH; Figure 3b),
Ad.IHH and Ad.TGF-b1 (IHH + TGF-b1; Figure 3c), or
Ad.IHH and Ad.BMP-2 (IHH + BMP-2; Figure 3d)
induced a significant chondrogenic response in the
Table 1 Primer details used for RT-PCR analyses
Gene RT-PCR primer sequences (5’ to 3’) Annealing temperature (°C) Product size (base pairs) Cycles
Chondrogenic markers
COL type II Sense: TTTCCCAGGTCAAGATGGTC 58.0 374 35
Antisense: CTTCAGCACCTGTC CACCA
AGN Sense: TGAGGAGGGCTGGAACAAGTACC 54.0 392 30
Antisense: GGAGGTGGTAATTGCAGGGAACA
COMP Sense: CAGGACGACTTTGATGCAGA 54.0 312 32
Antisense: AAGCTGGAGCTGTCTGGTA
FMD Sense: CTTACCCCTATGGGGTGGAT 54.0 389 35
Antisense: GTACATGGCCGTGAGGAAGT
SOX9 Sense: ATCTGAAGAAGGAGAGCGAG 58.0 263 35
Antisense: TCAGAAGTCTCCAGAGCTTG
Hypertrophy and osteogenic markers
COL type X Sense: CCCTTTTTGCTGCTAGTATCC 54.0 468 25
Antisense: CTGTTGTCCAGGTTTTCCTGGCAC
OP Sense: ACGCCGACCAAGGAAAACTC 51.0 483 35
Antisense: GTCCATAAACCACACTATCACCTCG
COL type I Sense: GGACACAATGGATTGCAAGG 54.0 461 32
Antisense: TAACCACTGCTCCACTCTGG
OC Sense: ATGAGAGCCCTCACACTCCTC 59.0 387 35
Antisense: GCCGTAGAAGCGCCGATAGGC
ALP Sense: TGGAGCTTCAGAAGCTCAACACCA 51.0 454 35
Antisense: TCTCGTTGTCTGAGTACCAGTCC
Internal control
EF-1a Sense: AGGTGATTATCCTGAACCATCC 54.0 234 25
Antisense: AAAGGTGGATAGTCTGAGAAGC
AGN, aggrecan core protein; ALP, alkaline phosphatase; COL, collagen; COMP, cartilage oligomeric matrix protein; EF-1a, elongation factor 1a; FMD, fibromodulin;
OC, osteocalcin; OP, osteopontin; SOX9, sex determining region Y-box 9.
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respective pellet cultures over time compared with the
Ad.GFP cultures (positive control; Figure 3a), which
were not chondrogenic. Cellularity of the respective
groups after 10 and 21 days is shown by H & E staining
of representative aggregate sections in Figure 3a, b (left
panels). Chondrogenic differentiation was evidenced by
strong metachromatic staining for proteoglycans with
Alcian Blue (Figure 3a to 3d, right panels) in the
extracellular matrix of the IHH, IHH + TGF-b1, and
IHH + BMP-2 pellets compared with the marker gene
negative controls. Only the comparative positive control
groups TGF-b1 or BMP-2 also revealed a chondrogenic
phenotype for both stains (Figure 3e).
Correspondingly, immunohistochemistry for cartilage
matrix proteins COL type II (Figure 4a to 4d, left
panels) and CS4 (Figure 4a to 4d, right panels) showed
Figure 1 Multilineage differentiation assays of bone marrow-derived mesenchymal stem cells. After 3 weeks of pellet culture,
mesenchymal stem cells (MSCs) maintained in the presence of transforming growth factor beta (TGF-b1) revealed strong chondrogenic
induction as evidenced by strong staining with Alcian Blue, while controls without TGF-b1 were not chondrogenic (left panels). Monolayer
cultures of MSCs responded equivalently to culture with osteogenic medium for 2 weeks in terms of strong staining for alkaline phosphatase
(ALP) and matrix mineralisation with Alizarin Red as opposed to the weak staining revealed by the negative controls (middle panels).
Adipogenesis was observed after 2 weeks of monolayer culture in adipogenic media by staining with Oil Red O for lipid droplets, while only
negative staining was detected in the respective control cultures (right panels).
Figure 2 Transgene expression of mesenchymal stem cell aggregates following adenoviral Indian hedgehog gene transfer. Primary
mesenchymal stem cells were modified with Ad.GFP (controls), Ad.IHH alone (IHH), or in combination with Ad.TGF-b1 (IHH + TGF-b1) or Ad.
BMP-2 (IHH + BMP-2), seeded into pellets and analysed during a 21-day time course. Values represent levels of (a) IHH, (b) TGF-b1, or (c) BMP-2
transgene product in the conditioned media by the respective groups over 24 hours at the time points indicated. Mean ± standard deviation
from three aggregates per condition and marrow preparation from three marrow preparations from different patients is shown. *Significant
differences (P < 0.05) compared with controls. Ad., adenoviral vector; BMP, bone morphogenetic protein; IHH, Indian hedgehog; TGF-b,
transforming growth factor beta.
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Figure 3 Histological assessment of chondrogenesis in mesenchymal stem cell aggregates after adenoviral Indian hedgehog gene
transfer. Following genetic modification with (a) Ad.GFP (negative control), (b) Ad.IHH (IHH), (c) Ad.IHH and Ad.TGF-b1 (IHH + TGF-b1), (d) Ad.
IHH and Ad.BMP-2 (IHH + BMP-2), or (e) Ad.TGF-b1 or Ad.BMP-2 only (positive control; TGF-b1 or BMP-2) at 5 × 102 virus particles/cells,
mesenchymal stem cells were maintained as pellets for 3 weeks until aggregates were harvested and processed. Representative sections after 10
and 21 days are shown. Left: H & E staining for evaluation of cellularity and cell morphology. Right: Metachromatic staining with Alcian Blue for
detection of matrix proteoglycans. Panels reproduced at low (50×; bar = 200 μm) and high (200×; bar = 50 μm) magnification as indicated. Ad.,
adenoviral vector; BMP, bone morphogenetic protein; IHH, Indian hedgehog; TGF-b, transforming growth factor beta.
Figure 4 Immunohistochemical analyses for cartilage matrix proteins of mesenchymal stem cell aggregate culture after chondrogenic
induction. Cells were infected with (b) Ad.IHH, (c) Ad.IHH + Ad.TGF-b1, (d) Ad.IHH + Ad.BMP-2, or (a) Ad.GFP (control) at 5 × 102 virus
particles/cells, and immunohistochemical stainings were performed on culture days 10 and 21 or representative sections for collagen type II (left
panels) and chondroitin-4-sulfate (right panels). Regions of positive immunostaining appear red. Panels are reproduced at low (50×; bar = 200
μm) and high (200×; bar = 50 μm) magnification as indicated. Ad., adenoviral vector; BMP, bone morphogenetic protein; IHH, Indian hedgehog;
TGF-b, transforming growth factor beta.
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a strong production of these cartilage matrix proteins
at days 10 and 21 of culture in the IHH (Figure 4b),
IHH + TGF-b1 (Figure 4c), and IHH + BMP-2 aggregates
(Figure 4d) relative to the Ad.GFP controls (Figure 4a),
which showed only very low levels of staining for both
markers. Clear-cut differences in the chondrogenic
appearance of the immunophenotype between the IHH,
IHH + TGF-b1, and IHH + BMP-2 aggregates were not
observed (Figure 4b to 4d).
Aggregates transduced with TGF-b1 or BMP-2 only, as
well as untransduced pellets maintained in the presence
of 10 ng/ml recombinant TGF-b1 protein, were all also
chondrogenic, while control cultures without gene or
growth factor supplementation were nonchondrogenic,
by means of positive staining for Alcian Blue (Figure 1,
left panels) and immunohistochemistry (data not shown)
for COL type II and CS4. This finding corresponds with
findings published extensively in previous work [8,11,15].
Hypertrophic differentiation and apoptosis
Immunohistochemistry for COL type × (Figure 5a to 5d,
left panels) and staining for ALP (Figure 5a to 5d, right
panels) were performed on representative aggregate
sections after days 10 and 21 of culture and were used as
markers for chondrocyte hypertrophy. Negative controls
(Ad.GFP) showed no detectable staining for COL type ×
(Figure 5a, left panels) and ALP (Figure 5a, right panels).
In contrast, stronger staining for COL type × (left panels)
and ALP (right panels) was found in all chondrogenic
groups of aggregates tested (Figure 5b to 5e). Notably,
the strongest staining of the matrix for Col type X was
seen in the IHH only group (Figure 5b, left panels), while
the most extensive staining for ALP was seen the IHH +
BMP-2 group and the BMP-2-only positive controls after
21 days of culture (Figure 5d, e, right panels).
For evaluation of cell viability and apoptosis (Figure 6)
following adenoviral gene transfer using IHH gene
transfer alone (Figure 6b) or in combination with TGF-
b1 (Figure 6c) or BMP-2 (Figure 6d) compared with
untransduced controls (Figure 6a), aggregate cultures
were examined using double fluorescence staining with
Annexin 5-Cy3/6-carboxyfluorescein diacetate. All
groups revealed equivalent high levels of green fluores-
cence (viable cells) after 10 and 21 days of culture (left
panels). In the apoptosis detection assay (Figure 6, right
panels), only very few cells were Annexin 5-positive (red
Figure 5 Histological and immunohistochemical analyses for hypertrophy of mesenchymal stem cell aggregate culture after
chondrogenic induction. After genetic modification with (a) Ad.GFP (negative control), (b) Ad.IHH (IHH), (c) Ad.IHH + Ad.TGF-b1 (IHH + TGF-
b1), (d) Ad.IHH + Ad.BMP-2 (IHH + BMP-2), or (e) Ad.TGF-b1 or Ad.BMP-2 only (positive control; TGF-b1 or BMP-2) at 5 × 102 virus particles/cells,
the aggregate cultures were processed and stained at culture days 10 and 21 for collagen type × (left panels) and alkaline phosphatase (right
panels). Regions of positive staining appear brown (left panels) or blue (right panels). Panels are reproduced at low (50×; bar = 200 μm) and
high (200×; bar = 50 μm) magnification as indicated. Ad., adenoviral vector; BMP, bone morphogenetic protein; IHH, Indian hedgehog; TGF-b,
transforming growth factor beta.
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fluorescent) in the control group (Figure 6a), as well as
in the IHH group (Figure 6b) or the IHH + TGF-b1
group (Figure 6c), while many Annexin 5-positive cells
were found in the IHH + BMP-2 group (Figure 6d).
Biochemical analyses of cell proliferation, GAG content
and ALP activity
As primary MSCs were shown to be amenable to adeno-
viral gene transfer, and to undergo chondrogenesis upon
stimulation with IHH alone or in combination with
TGF-b1 or BMP-2, we examined the effects of these
treatments on cell proliferation using the ATP assay
compared with marker gene transduced controls (Figure
7a). Initially, at days 3 and 7, cell proliferation rates in
MSC aggregates were high, and they declined over time
thereafter, without significant differences between all
groups tested (Figure 7a).
Quantitative assessment of GAG synthesis revealed
significantly enhanced GAG levels of all treatment
groups that received IHH relative to controls (Figure
7b), while major differences in the pattern of GAG
synthesis over time among the chondrogenic groups
IHH, IHH + TGF-b1, or IHH + BMP-2 could not be
resolved (Figure 7b).
Chondrogenic hypertrophy was quantified using ALP
activity (Figure 7c), which was found significantly ele-
vated at days 7, 14 and 21 of culture in the IHH +
BMP-2 modified aggregates compared with all other
groups, whereas significantly higher values in the IHH +
TGF-b1 transduced cultures compared with the GFP
controls could only be resolved at day 21 (Figure 7c).
Evaluation of chondrogenic marker gene expression over
time
To explore the effects of IHH gene delivery alone or in
combination with TGF-b1 or BMP-2 on chondrogenesis
and hypertrophy compared with controls, we examined
the time course for expression of genes associated with
chondrogenesis and hypertrophic maturation using
semi-quantitative RT-PCR (Figure 8).
Expressions of mRNAs from the chondrogenic marker
genes COL type II, AGN, COMP, fibromodulin and
SOX9 were upregulated in the IHH, IHH + TGF-b1, and
IHH + BMP-2 groups compared with controls (Ad.GFP),
which were not chondrogenic and expressed only very
low levels of the chondrogenic genes COL type II, AGN,
fibromodulin and SOX9 (Figure 8a). Although expressed
at lower levels compared with the chondrogenic groups
IHH, IHH + TGF-b1, and IHH + BMP-2, above-baseline
levels of expressions were found for COMP in the Ad.
GFP controls (Figure 8a). Clear-cut differences in the
expression pattern of the chondrogenic markers between
the chondrogenic groups IHH, IHH + TGF-b1, or IHH +
BMP-2 could not be resolved (Figure 8a).
Similarly, temporal expression profiles of mRNAs asso-
ciated with chondrogenic hypertrophy and osteogenesis
revealed elevated levels in all groups and time points tested
for COL type I, COL type X, ALP, OP, and osteocalcin at
Figure 6 Analyses for cell viability and apoptosis within mesenchymal stem cell pellets after chondrogenic induction. Following genetic
modification with (b) Ad.IHH (IHH), (c) Ad.IHH + Ad.TGF-b1 (IHH + TGF-b1), (d) Ad.IHH + Ad.BMP-2 (IHH + BMP-2) and (a) Ad.GFP (negative
control) at 5 × 102 virus particles/cells, cultures were double-stained with 6-carboxyfluorescein diacetate (CFDA) (left panels) and Annexin 5 (right
panels) at days 10 and 21 of culture. Representative fluorescence microscopy images are shown. Note that living cells are stained green with
CFDA, late apoptotic cells red with Annexin 5-Cy3, while early apoptotic cells stained for both CFDA and Annexin 5. Panels are reproduced at
low (50× bar = 200 μm) or high (200×; bar = 50 μm) magnification as indicated. Ad., adenoviral vector; BMP, bone morphogenetic protein; IHH,
Indian hedgehog; TGF-b, transforming growth factor beta.
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days 3, 7, 14 and 21 of culture (Figure 8b). While the chon-
drogenic groups IHH, IHH + TGF-b1, and IHH + BMP-2
showed markedly increased mRNA levels for COL type X
and ALP compared with the marker gene controls, expres-
sions for COL type I, OP and osteocalcin appeared not to
be strongly regulated by the different groups (Figure 8b).
Again, major differences between the different chondro-
genic groups IHH, IHH + TGF-b1, or IHH + BMP-2 could
not be detected.
Discussion
IHH belongs to the hedgehog protein family, which also
includes sonic hedgehog (SHH) and desert hedgehog
[21]. Following binding to their cell surface receptors
patched-1 and smoothened, hedgehog proteins signal via
members of the Gli family of transcription factors (Gli1,
Gli2 and Gli3) at the end of the pathway, which are
essential regulators of cell fate and patterning in the
developing skeleton [22]. In this work, we used the pel-
let culture system to analyse whether adenoviral delivery
of IHH can lead to chondrogenesis of primary MSCs in
vitro, and to evaluate the extent of hypertrophy alone
and together with TGF-b1 or BMP-2.
Delivery of IHH via adenoviral vectors alone or in com-
bination led to reproducible chondrogenesis in human
MSC pellet cultures, as shown qualitatively by staining
Figure 7 Biochemical analyses of mesenchymal stem cell aggregates following chondrogenic induction. Primary mesenchymal stem cells
were infected with Ad.GFP (controls), Ad.IHH alone (IHH), or in combination with TGF-b1 (IHH + TGF-b1) or BMP-2 (IHH + BMP-2), placed into
aggregate cultures and assayed biochemically over a 3-week time course. (a) Cell proliferation was evaluated using the ATP assay, and (b)
glycosaminoglycan (GAG) content and (c) relative alkaline phosphatase (ALP) activity normalised to DNA are shown for quantification of cartilage
matrix production and hypertrophy, respectively. Bars represent mean ± standard deviation from three pellets per group and patient, assessed
on five marrow preparations from different patients. *Significant difference (P < 0.05) compared with marker gene-transduced controls. Ad.,
adenoviral vector; BMP, bone morphogenetic protein; IHH, Indian hedgehog; TGF-b, transforming growth factor beta.
Figure 8 Time course of gene expression assessed by semiquantitative RT-PCR of mesenchymal stem cell pellet cultures. Pellets
transduced with Ad.GFP (control), Ad.IHH alone (IHH), or Ad.IHH in combination with Ad.TGF-b1 (IHH + TGF-b1) or BMP-2 (IHH + BMP-2) were
analysed over time. (a) Expressions for the chondrogenic mRNAs collagen (COL) type II, aggrecan core protein, cartilage oligomeric matrix
protein (COMP), fibromodulin, or sex determining region Y-box 9 (SOX9) at days 3, 7, 14, or 21 of culture are shown, respectively. (b) Expressions
of mRNAs associated with chondrogenic hypertrophy and osteogenesis of COL type I, COL type X, alkaline phosphatase, osteopontin, or
osteocalcin at days 3, 7, 14, or 21 of culture are shown, respectively. Expressions of elongation factor-1a served as the housekeeping gene and
internal control. Primer details are shown in Table 1. Ad., adenoviral vector; BMP, bone morphogenetic protein; IHH, Indian hedgehog; TGF-b,
transforming growth factor beta.
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with Alcian Blue, COL type II and CS4 (Figures 3 and 4)
and quantitatively using the GAG assay (Figure 7b). This
corresponds to findings in the same model, when adeno-
viral delivery of TGF-b1 [8,15], BMP-4 [11] or BMP-2
[8,11,15] was used. However, combined delivery of IHH
together with TGF-b1 or BMP-2 was not able to elicit
synergistic effects with respect to the extent of chondro-
genesis compared with single IHH delivery (Figures 3, 4
and 7b). This is in agreement with findings of combined
gene delivery of TGF-b1 and BMP-2 in the same setup,
where additive effects were also absent [23]. In contrast,
synergistic effects on transgene expression and chondro-
genesis were reported, when TGF-b1 or BMP-2 were
administered together with insulin-like growth factor-1
(IGF-1) [23], indicating that the choice of transgenes
plays pivotal roles to induce additive chondrogenic
effects. Furthermore, increased dosing of adenoviral vec-
tors was shown to be detrimental for chondrogenesis in
this model [23], which was the main reason for not
increasing the adenoviral dosage in this study. Notably,
pellet cultures of all groups decreased levels of cell prolif-
eration over time, with the highest levels being seen in
the IHH + BMP-2 groups (Figure 7a). This also corre-
sponds to previous findings, where high levels of cell
proliferation and metabolic activity were seen in BMP-4-
modified and BMP-2-modified aggregates throughout the
3 weeks of culture [11]. Furthermore, signs of chondro-
genic hypertrophy were noticed in MSC pellet cultures
transduced with IHH alone and together with TGF-b1,
but were most abundant in the IHH + BMP-2 group, as
assessed by expression for ALP, COL type X and
Annexin 5 (Figures 5 and 6). This also concurs with pre-
vious results, where BMP-2-infected pellets revealed
higher levels of hypertrophy compared with TGF-b1 [23]
or BMP-4 [11].
The data on expression of marker genes for chondro-
genesis and hypertrophy (Figure 8) are in general agree-
ment with the biochemical (Figure 7) and histological
observations (Figures 3 to 6), showing strong presence of
chondrogenic transcripts in aggregates after IHH stimu-
lation, such as COL type II, AGN, COMP and SOX9.
Levels of mRNAs encoding the hypertrophy-associated
genes COL type X and OP were also present in all IHH-
modified groups, compared with controls (Figure 8), and
are in general agreement with previous observations
where gene delivery of BMP-2 revealed high levels of
hypertrophy [11,23].
Our results are in agreement with those of Kellner
and colleagues, who used recombinant hedgehog pro-
teins for generation of chondrocyte-based cartilage con-
structs in vitro [24]. In their study, recombinant IHH
was as effective as the protein family member SHH to
increase levels of GAG synthesis, when proteins were
used in dipalmitoylated form at 1,000 ng/ml [24]. In our
study, however, IHH was detected at much lower con-
centration (Figure 2a) but was also very efficient in sti-
mulating chondrocyte matrix synthesis by MSC
aggregates (Figures 3, 4 and 7b), which is probably due
to the efficient pericellular distribution of the IHH
transgene product following adenoviral transduction.
Our data also correspond to positive effects of hedge-
hog proteins seen in chondrogenic murine ATDC5 or
RMD-1 cells in vitro, where administration of transgenic
IHH and SHH led to increased chondrogenic matrix
formation [25]. In contrast to our study, however, Eno-
moto-Iwamoto and colleagues report on additive effects
by treatment of IHH or SHH together with BMP-2 pro-
tein, which we attribute to the differences in protein
delivery and target cell that were used in both experi-
mental settings. This study also showed that IHH and
SHH administration upregulated the expression of Ptc-1
and Gli-1 in RMD-1 and ATDC-5 cells, while Smo,
BMP-2 and BMP-4 were unregulated but present and
BMP-5 and BMP-7 were undetectable in these cell types
[25], indicative of the major regulatory chondrogenic
pathways that are also likely to be involved in our study
using adult human MSCs.
Furthermore, experiments in SHH knockout mice with
defective tracheal cartilage formation revealed that
SOX9 was a downstream regulator of SHH, and that
cartilage formation by exogenous administration with
either SHH or BMP-4 could be rescued, indicating
important roles for both factors on chondrogenesis [26].
This corresponds to in vitro data from ATDC-5 cells,
where exogenously administered IHH upregulated the
gene expression of COL type X and osteoprotegerin
ligand, while it did not modulate the expression of IHH
itself, BMP-4, BMP-6, TGF-b1, or TGF-b2 [27].
Nonetheless, there are also in vivo data on the forma-
tion of ectopic cartilage and bone in nude mice after
intramuscular SHH and IHH administration [25], indi-
cating the regenerative potential of such methodology.
Moreover, Grande and colleagues were able to show
improved cartilage regeneration in vivo, when genetically
modified periosteal cells to express SHH or BMP-7 were
administered orthotopically to osteochondral defects in a
rabbit model [28]. Although no differences between both
factors were delineated in this study, the issue of hyper-
trophy in the context of hedgehog factors was not further
examined [28].
Much of the current knowledge about IHH is derived
from research in the developing skeleton, where chondro-
cytes are condensed into cartilage elements during the
process of endochondral ossification, and progress
through stages of proliferation and hypertrophic differen-
tiation, before they ultimately terminally differentiate,
undergo apoptosis and are replaced by bone [29]. IHH has
been shown to be involved as key regulator during several
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of these processes [14]. First, IHH is required for synthesis
of PTHrP and interacts with PTHrP in a negative feedback
loop regulating the pace of hypertrophic differentiation
[30,31]. Apart from the action of IHH via PTHrP, further
studies also indicate direct independent effects of IHH on
chondrocyte proliferation and the ossification process,
thus coordinating several different steps of endochondral
bone formation [29,32]. Furthermore, the transcription
factor Alf4 was shown to be required in chondrocytes for
IHH expression, which subsequently, via the paracrine
effects of IHH, dominates the role of Alf4 in osteoblasts
during development for the control of early osteogenesis
and skeletal growth [33]. Postnatally, the growth plate
undergoes major structural and functional changes, with
PTHrP being expressed in resting zone cartilage - a site
that differs from the embryonic source, the periarticular
cells - supporting the hypothesis that the embryonic IHH-
PTHrP feedback loop is maintained in the postnatal
growth plate [34]. These observations from the developing
skeleton grossly correspond to our findings using adult
MSCs, as IHH was shown be able to effectively induce and
regulate several steps during chondrogenesis, including
proliferation, differentiation, hypertrophy and apoptosis
(Figures 2 to 7). Forced overexpression of IHH, however,
might have resulted in an imbalance within the finely
tuned regulative system with PTHrP that may have influ-
enced the missing modulation of hypertrophy in our sys-
tem. This is in contrast to the findings of Minina and
colleagues in the cartilage elements of transgenic mice,
where IHH overexpression resulted in a delayed onset of
hypertrophic differentiation [35].
Notably, IHH only revealed the strongest staining of
the matrix with COL type X and only very low levels of
ALP activity, while most extensive staining for ALP was
seen in the IHH + BMP-2 group and the BMP-2-only
positive controls with only pericellular COL type X stain-
ing (Figure 5). This indicates that COL type X and ALP,
both markers for chondrogenic hypertrophy, might be
differentially regulated by IHH or BMP-2. This corre-
sponds to findings of our own group and others in MSCs
using TGF-b1 or BMP-2 [15,23], TGF-b1 or thyroid hor-
mone [36], or BMP-4 or BMP-2 [11,37], where a similar
differential regulation of these markers could also be
observed. This is also in agreement with findings in the
literature on different cell types, where COL type X pre-
cedes ALP expression in growth plate chondrocytes
[38,39], costal cartilage [40] or MSCs [12].
This corresponds to elevated levels of COL type II and
reduced levels of COL type X expression by TGF-b1-sti-
mulated MSC aggregates upon stimulation with PTH
hormone [41] or PTHrP in vitro [12,42]. Reduced levels
of hypertrophy were also confirmed, when recombinant
PTHrP was employed in an ectopic model of chondro-
genesis in vivo using adult MSCs [12,42,43]. In our
system, however, using adenoviral IHH gene delivery in
vitro, no inhibitory effects on chondrogenic hypertrophy
were evident. This pattern might change when IHH
genes are delivered to cartilage defects in vivo - the clari-
fying experiments are underway.
Interestingly, during endochondral ossification, several
other groups of signalling systems have been found to
interact with IHH [29]. For example, several BMPs, such
as BMP-2, are thought to act downstream of IHH, ser-
ving as secondary signals mediating the IHH signals to
the periarticular perichondrium to induce PTHrP [29].
BMPs might also reciprocally act back on the prehyper-
trophic chondrocytes, thereby coordinating hypertrophic
differentiation with the differentiation of the periosteum
[29]. This is in agreement with reports of BMP-2 action
on chondrogenesis and hypertrophy, which are in part
regulated via HIF1a activation and vasculature formation
[44]. This corresponds to our data, as highest levels of
hypertrophy and apoptosis were seen in the group that
co-expressed IHH and BMP-2 or BMP-2 alone, com-
pared with the IHH + TGF-b1 or IHH only groups
(Figures 5 to 8). This corresponds to the findings in sev-
eral transgenic mouse models showing that, in particular,
BMP-2 and TGF-b1 can have agonistic and antagonistic
effects on proliferation and chondrogenesis and IHH reg-
ulation [45].
Moreover, IGF-1 seems also to be importantly involved
in IHH/PTHrP signalling - as cartilage-specific IGF-1
receptor knockout mice revealed growth retardation with
reduced chondrocyte proliferation and decreased IHH
expression, while PTHrP was upregulated [33]. This invol-
vement could also be confirmed in vitro using in IGF-1
receptor knockout in adult cells, indicating that the IGF-1
receptor in chondrocytes controls cell growth, survival,
and differentiation in embryonic and postnatal growth in
part by regulating the IHH/PTHrP pathway [33].
Finally, there are many more regulators of chondrocyte
hypertrophy and terminal differentiation such as vitamin
D3 [46,47] or fibroblast growth factor receptor-3 [29],
which are also interacting with the IHH/PTHrP pathway -
and it becomes more obvious that the single steps of
endochondral ossification are tightly coordinated, which in
the same way basically holds true for in vitro chondrogen-
esis and hypertrophy of adult MSCs. Although significant
progress has been made during the last years in analysing
the signals regulating endochondral ossification in the
developing embryo, complete understanding of the control
system in adult cells and tissues will require further exten-
sive studies.
Conclusion
IHH gene transfer via adenoviral vectors alone and in
combination with TGF-b1 or BMP-2 efficiently induces
chondrogenesis in aggregate cultures of human primary
Steinert et al. Arthritis Research & Therapy 2012, 14:R168
http://arthritis-research.com/content/14/4/R168
Page 11 of 13
MSCs. The appearance of chondrocyte hypertrophy in
this system following 3 weeks of in vitro culture could
not be obviated by IHH, however, and was strongly pre-
sent when BMP-2 was co-expressed. Whether IHH can
induce chondrogenesis while modulating hypertrophy in
vivo therefore remains to be seen. This gene transfer
technology might thus be used to improve the outcome
of MSC-based approaches to cartilage regeneration in
humans in the future.
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